ANAPTYSBIO INC(NASDAQ:ANAB) stock News

ANAB Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

a month ago - By: Benzinga

Analyst Expectations For AnaptysBio's Future

a month ago - By: The Motley Fool

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

a month ago - By: Zacks Investment Research - Mentions: AGEN

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

2 months ago - By: Benzinga

Analyst Expectations For AnaptysBio's Future

a month ago - By: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

a month ago - By: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

a month ago - By: Zacks Investment Research - Mentions: ACIU

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

6 months ago - By: AnaptysBio, Inc.

Anaptys Announces Stock Repurchase Plan

3 months ago - By: AnaptysBio, Inc.

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

3 months ago - By: AnaptysBio, Inc.

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

4 months ago - By: AnaptysBio, Inc.

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

4 months ago - By: AnaptysBio, Inc.

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

4 months ago - By: Yahoo Finance - Mentions: BLK XERS BEN COMP ...

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

4 months ago - By: Yahoo Finance - Mentions: BLK BEN

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

4 months ago - By: Yahoo Finance - Mentions: BLK ACMR BEN APP ...

ACM Research, Inc. (ACMR): Among the Unstoppable Growth Stocks to Invest in Now

4 months ago - By: Yahoo Finance - Mentions: BLK PGY BEN DIS ...

Is Pagaya Technologies (PGY) the Unstoppable Growth Stock to Invest in Now?

4 months ago - By: Yahoo Finance - Mentions: BLK DUOL BEN CELH ...

Is Duolingo, Inc. (DUOL) the Unstoppable Growth Stock to Invest in Now?

4 months ago - By: Zacks Investment Research - Mentions: SEER

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: AnaptysBio, Inc.

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: AnaptysBio, Inc.

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Bright Peak Therapeutics, Inc. - Mentions: DSGN XERS

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

6 months ago - By: AnaptysBio, Inc.

Anaptys Announces Stock Repurchase Plan

7 months ago - By: AnaptysBio, Inc.

ANAPTYSBIO INC (ANAB) Stock News

ANAB Latest News, Press Relases and Analysis

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Participation in September Investor Conferences

Analyst Expectations For AnaptysBio's Future

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Analyst Expectations For AnaptysBio's Future

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

ACM Research, Inc. (ACMR): Among the Unstoppable Growth Stocks to Invest in Now

Is Pagaya Technologies (PGY) the Unstoppable Growth Stock to Invest in Now?

Is Duolingo, Inc. (DUOL) the Unstoppable Growth Stock to Invest in Now?

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update